AQA A-Level Biology: Gene Expression and Technology — Complete Revision Guide (7402)

Gene expression and technology is the section of AQA 7402 that takes the static picture of the genome — encoded by DNA, organised into chromosomes, transmitted through meiosis — and turns it into a dynamic system. Why is every cell in your body genetically near-identical and yet a neuron is nothing like a hepatocyte? Why does smoking dramatically raise the lifetime risk of lung cancer? Why can a forensic laboratory match a sample of saliva to an individual from a population of millions using a tube of buffer, some primers and a thermocycler? Why does a single point mutation in a transcription factor cause a developmental disorder while the same mutation in a structural gene might be silent? All these questions sit in section 3.8 of the specification, and all of them are routinely examined.

Section 3.8 is the tenth course in the LearningBro AQA A-Level Biology path and consolidates the molecular biology of the earlier sections (DNA structure, protein synthesis, mutation, meiosis) into a framework for understanding regulation, differentiation, disease and biotechnology. The completed Phase 2 version of the course adds dedicated treatment of transcription factors and of cancer biology, which between them give the section the regulatory and clinical depth that A* candidates need to handle Paper 3 essay prompts on gene expression. Get this course fluent and the synoptic links to inheritance, evolution and the practical biotechnology questions on Paper 2 fall into place; skim it and you will struggle with the most lucrative high-mark items on the synoptic paper.

Guide Overview

The course breaks AQA 3.8 into eight lessons. Start with transcription factors and gene regulation, which establishes how cells turn the same genome into different proteomes. Continue with epigenetics for the heritable but non-sequence-based mechanisms of gene control. The stem cells and differentiation lesson treats totipotency, pluripotency and the regenerative-medicine implications. Oncogenes, tumour suppressors and cancer covers the molecular basis of malignancy and the distinction between gain-of-function and loss-of-function mutations. Recombinant DNA technology covers restriction enzymes, ligation, plasmid vectors and bacterial transformation. PCR and gel electrophoresis walks through the standard amplification and separation toolkit. Genetic fingerprinting and forensics treats VNTRs, STRs and the statistical interpretation of match probabilities. The course closes with gene therapy and genome projects, which covers clinical applications and the era of large-scale sequencing.

AQA 7402 Specification Coverage

AQA A-Level Biology (7402) is assessed through three written papers at the end of year 13. Gene expression content sits in section 3.8 of the specification (refer to the official AQA specification document for exact wording). Section 3.8 is examined heavily on Paper 2 and Paper 3, with Paper 3 frequently using a gene-expression scenario as the basis for an extended-response or synoptic essay question.

Sub-topic	Spec area	Typical paper weight
Alteration of gene expression: transcription factors	3.8.2.1	4-6 marks
Epigenetic control of gene expression	3.8.2.2	3-5 marks
Stem cells and totipotency	3.8.2.3	3-5 marks
Tumour formation: oncogenes and tumour suppressors	3.8.3	4-6 marks
Mutations and genetic variation	3.8.1	2-4 marks
Recombinant DNA technology	3.8.4.1	4-6 marks
PCR and gel electrophoresis	3.8.4.2	3-5 marks
Genetic fingerprinting	3.8.4.3	3-5 marks
Gene therapy and genome projects	3.8.4	3-5 marks

These weights are estimates, modelled on recent 7402 papers. What is reliable is that a transcription-factor or epigenetics item, a cancer-biology stem and a biotechnology calculation appear in some form on essentially every series, and that Paper 3 essay prompts often choose gene expression as their backbone topic.

Transcription Factors and Gene Regulation

A transcription factor is a protein that binds to specific DNA sequences in the promoter or enhancer region of a target gene and either stimulates or represses transcription by RNA polymerase. The classical eukaryotic example is the oestrogen receptor: oestrogen diffuses across the cell membrane (steroid hormones being lipid-soluble), binds the receptor in the cytoplasm, the complex translocates to the nucleus, binds to oestrogen-response elements upstream of target genes and activates their transcription. The hormone-receptor complex is the transcription factor; binding to DNA is the rate-limiting regulatory step.

Other named examples on the AQA specification include the lac operon regulatory proteins in prokaryotes (LacI repressor, CAP activator) and the developmental transcription factors that orchestrate body-plan specification. The principle generalises: cells with different functions express different sets of transcription factors, which in turn set up different patterns of downstream gene expression. The same DNA, regulated differently, produces a neuron in one cell and a hepatocyte in another.

A small but important subtopic is the action of siRNA (small interfering RNA). Double-stranded RNA is processed by Dicer into 21-23 nucleotide fragments that bind to complementary mRNA and target it for degradation by the RISC complex. This post-transcriptional gene silencing was the subject of work by Fire and Mello on Caenorhabditis elegans and has both research and therapeutic applications. AQA examines the mechanism and the basic outcome (target mRNA destroyed, protein not produced).

A common pitfall is to confuse transcription factors (proteins binding DNA) with siRNA (RNA binding mRNA). Another is to describe oestrogen as "switching on a gene" without naming the receptor complex, the response element or the polymerase recruitment.

See the transcription factors lesson.

Epigenetics

Epigenetic modifications are heritable changes in gene expression that do not involve alterations to the DNA sequence. The two AQA-examined mechanisms are DNA methylation and histone modification. Methylation of cytosine bases in CpG dinucleotides, typically clustered at gene promoters, tends to silence transcription by impeding transcription-factor binding and recruiting repressive chromatin-modifying enzymes. Histone modification — acetylation of lysine residues on histone tails neutralises positive charges, loosens the histone-DNA interaction and opens chromatin for transcription; deacetylation reverses the effect. Methylation of histones can either activate or repress depending on which residue is modified.

Epigenetic marks are partially heritable through mitosis and, in some cases, through meiosis. Environmental influences — diet, stress, exposure to toxins — can alter epigenetic patterns. The classical example AQA cites is the Dutch hunger winter of 1944-45, where prenatal exposure to famine has been associated with altered methylation patterns and elevated disease risk in adulthood as documented in the epidemiological and molecular literature. Epigenetic dysregulation is a contributor to cancer; many cancers show genome-wide hypomethylation alongside specific hypermethylation of tumour-suppressor gene promoters.

A common pitfall is to describe epigenetic changes as alterations to the DNA sequence. They are not — they are chemical modifications to DNA bases (methylation) or to associated proteins (histones). Another is to overstate transgenerational inheritance; the evidence base is real but the magnitudes are debated.

See the epigenetics lesson.

Stem Cells and Differentiation

A stem cell is a cell capable of self-renewal and of differentiation into one or more specialised cell types. AQA recognises a potency hierarchy. Totipotent cells can form every cell type in the embryo plus extra-embryonic tissues (placenta, yolk sac); in mammals, only the zygote and the first few divisions retain totipotency. Pluripotent cells (embryonic stem cells, ES cells) can form every cell type in the body but not extra-embryonic tissues. Multipotent adult stem cells (haematopoietic stem cells in bone marrow, neural stem cells in specific brain regions) can form a restricted range of related cell types. Unipotent progenitor cells can only form a single cell type but retain self-renewal.

Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed back to a pluripotent state by forced expression of a small set of transcription factors. The technique, developed by Yamanaka and colleagues with mouse fibroblasts and subsequently human cells, sidesteps the ethical concerns associated with embryonic stem cell derivation and supplies patient-matched cell sources for regenerative medicine and disease modelling.

Therapeutic applications discussed by AQA include bone-marrow transplantation for leukaemia, retinal stem-cell therapy for macular degeneration, and the active research programmes in cardiac repair, spinal cord injury and pancreatic islet replacement for type 1 diabetes. Examiners reward candidates who can evaluate the technical and ethical trade-offs: ES cells offer the broadest potency but raise ethical concerns; iPSCs sidestep ethics but carry residual reprogramming-related cancer risk; adult stem cells are safer but limited in potency.

A common pitfall is to claim that all stem cells are pluripotent. The potency hierarchy is central to the topic. Another is to conflate "stem cell therapy" with cures; many programmes are in clinical trial rather than routine practice.

See the stem cells lesson.

Oncogenes, Tumour Suppressors and Cancer

Cancer is a disease of uncontrolled cell division resulting from accumulated mutations in genes that regulate the cell cycle. AQA distinguishes two classes of cancer-relevant gene, and the distinction is examined precisely — confusing the two is a guaranteed mark loss.

Proto-oncogenes code for proteins that stimulate cell division (growth-factor receptors, signal-transduction proteins, cell-cycle activators). A gain-of-function mutation converts a proto-oncogene into an oncogene — a hyperactive version that drives division regardless of normal regulatory signals. Named examples include RAS (a GTPase frequently mutated in pancreatic, colorectal and lung cancers), MYC (a transcription factor amplified in many tumour types) and HER2 (a growth-factor receptor overexpressed in a subset of breast cancers and targeted clinically by trastuzumab). Oncogenes are dominant at the molecular level — a single mutated allele is sufficient to drive the phenotype.

Tumour-suppressor genes code for proteins that restrain cell division or trigger apoptosis in damaged cells. A loss-of-function mutation removes the brake. Named examples include p53 (the "guardian of the genome", a transcription factor that triggers cell-cycle arrest or apoptosis in response to DNA damage, mutated in roughly half of all human cancers), BRCA1 and BRCA2 (DNA-repair proteins whose loss-of-function dramatically elevates breast and ovarian cancer risk) and RB1 (the retinoblastoma protein that gates the G1/S transition of the cell cycle). Tumour-suppressor mutations are typically recessive at the molecular level; both alleles must be inactivated before the cellular phenotype changes — Knudson's "two-hit hypothesis", first articulated for retinoblastoma.

Epigenetic silencing is a major route to tumour-suppressor inactivation. Hypermethylation of the promoter of p53, BRCA1 or other tumour suppressors can silence the gene without altering the DNA sequence. This links section 3.8 directly back to the epigenetics lesson and is a favourite Paper 3 synoptic prompt.

Targeted cancer therapies exploit the molecular distinction. Trastuzumab binds the HER2 receptor and blocks signalling in HER2-positive breast cancer. PARP inhibitors are selectively cytotoxic to BRCA-deficient tumours through synthetic lethality. The era of precision oncology — selecting therapy based on a tumour's specific molecular profile — is rapidly displacing the older one-size-fits-all chemotherapy approach.

A common pitfall is to label BRCA1, BRCA2 or p53 as oncogenes. They are tumour suppressors — loss-of-function, not gain-of-function. Another is to claim a single mutation causes cancer; the standard model is that cancer requires accumulation of multiple mutations across both oncogenes and tumour suppressors. Another is to describe "uncontrolled cell division" without specifying which regulatory pathway is disrupted.

See the oncogenes and tumour suppressors lesson.

Recombinant DNA Technology

Recombinant DNA technology is the toolkit for cutting, joining and propagating defined DNA fragments. Restriction endonucleases are bacterial enzymes that cut DNA at specific recognition sequences. Some leave blunt ends; others, more useful for downstream ligation, leave sticky ends with short single-stranded overhangs that re-anneal predictably. DNA ligase joins fragments by reforming the phosphodiester bond. Plasmid vectors are small circular DNA molecules in bacteria that carry the inserted fragment, typically alongside an antibiotic-resistance gene for selection of successfully transformed bacteria.

The standard workflow: cut the target DNA and a plasmid with the same restriction enzyme, mix the fragments with ligase, transform a bacterial culture with the resulting recombinant plasmids, plate on antibiotic-containing medium so only transformed bacteria survive, identify colonies carrying the desired insert (commonly with a reporter gene such as lacZ for blue-white screening), and scale up the chosen clone. The product is a defined recombinant DNA construct in unlimited supply.

Applications include the production of recombinant human proteins for therapy (insulin, human growth hormone, factor VIII for haemophilia), the engineering of genetically modified crops (Bt cotton, golden rice with engineered vitamin A precursors), and the construction of model organisms for research. The ethical and regulatory framework around GM organisms is examined: candidates are expected to evaluate trade-offs around yield, environmental impact, ownership of intellectual property and public acceptance.

A common pitfall is to muddle the sequence of steps. Cut, then ligate, then transform, then select — in that order. Another is to forget that the same restriction enzyme must be used on both fragments to generate complementary sticky ends.

See the recombinant DNA lesson.

PCR and Gel Electrophoresis

The polymerase chain reaction, developed by Mullis in the 1980s, amplifies a defined DNA fragment exponentially. The cycle: denaturation at around 95 °C separates the strands; annealing at around 50-65 °C lets short primer sequences (typically 18-25 nucleotides) hybridise to flanking regions of the target; extension at around 72 °C with Taq polymerase, a thermostable enzyme from Thermus aquaticus, synthesises new strands using the dNTP pool. Each cycle approximately doubles the target sequence, so 30 cycles produce roughly a billion-fold amplification from a single starting template.

The reaction mixture contains: template DNA, two specific primers (forward and reverse), the four dNTPs, Taq polymerase, magnesium ions as a cofactor and buffer. Primer design is the dominant practical skill — primers must flank the target, anneal at compatible temperatures and avoid self-complementarity. AQA exam items frequently give candidates a hypothetical PCR scenario and ask why a particular component matters; the standard answer routes back to the enzymology of polymerase and the chemistry of annealing.

Gel electrophoresis separates DNA fragments by size. The negatively charged DNA migrates through a porous agarose gel under an electric field; smaller fragments move faster. A size-standard ladder run in parallel allows fragment lengths to be estimated. The technique is used to verify PCR products, to size restriction-digest fragments and to interpret genetic fingerprint patterns.

A common pitfall is to confuse PCR (amplification) with electrophoresis (separation). PCR makes copies; electrophoresis sorts them by size. Another is to write that "DNA is positively charged" — the phosphate backbone makes DNA negatively charged, and migration runs from the negative electrode toward the positive.

See the PCR and gel electrophoresis lesson.

Genetic Fingerprinting and Forensics

Genetic fingerprinting, developed by Alec Jeffreys at Leicester in the 1980s, exploits the fact that humans (and other organisms) carry highly variable repetitive sequences in their non-coding DNA. VNTRs (variable number tandem repeats) and STRs (short tandem repeats) vary in copy number between individuals, generating a pattern of fragment lengths that is essentially unique to each person (excepting identical twins).

The modern forensic workflow uses PCR to amplify a panel of STR loci, gel or capillary electrophoresis to separate the products by size, and statistical analysis to compute the probability that two unrelated individuals would match by chance. Match probabilities of one in a billion or smaller are achievable with a sufficiently large STR panel. UK forensic practice uses a defined panel of loci managed by the National DNA Database.

Applications extend beyond forensic identification to paternity testing, immigration cases, archaeological work and wildlife forensics (identifying species in seized animal products). The ethical considerations around population-wide genetic databases — coverage, consent, data retention, racial bias in database representation — are examined: candidates should be able to evaluate the trade-offs.

A common pitfall is to claim genetic fingerprints come from coding regions; the variability that makes the technique work is concentrated in non-coding repetitive DNA. Another is to overstate match certainty without acknowledging the statistical underpinning.

See the genetic fingerprinting lesson.

Gene Therapy and Genome Projects

Gene therapy introduces a functional copy of a gene into a patient's cells to compensate for a disease-causing mutation. Somatic gene therapy modifies cells in the affected tissue; effects are not heritable. Germline gene therapy would modify cells in the germ line and would be heritable; it is currently prohibited in most jurisdictions for ethical reasons. Vector choice — viral (adenovirus, AAV, lentivirus) or non-viral (lipid nanoparticles, naked DNA) — is the dominant technical challenge.

Clinical successes include treatment of severe combined immunodeficiency (SCID), Leber's congenital amaurosis (an inherited form of blindness, addressed by AAV delivery to retinal cells) and a growing list of monogenic disorders treated with newer vector platforms. CRISPR-Cas9 genome editing, developed by Charpentier and Doudna among others, has opened the prospect of precise correction of disease-causing sequences rather than addition of a functional copy elsewhere in the genome — though clinical translation is recent and ethical scrutiny is intense.

The Human Genome Project, completed in draft form in 2001 and refined since, sequenced the human genome and laid the basis for personalised medicine. Subsequent large-scale efforts — 1000 Genomes Project, UK Biobank, gnomAD — have catalogued human genetic variation at population scale and are now integral to disease-association research. AQA expects candidates to understand the biological principle (sequence enables comparison, comparison enables function discovery, function discovery enables intervention) and to be able to discuss applications and ethical implications.

A common pitfall is to conflate gene therapy with germline editing. They are distinct in mechanism and in ethical status. Another is to overstate the speed of clinical translation; many genome-project findings have not yet produced approved therapies.

See the gene therapy and genome projects lesson.

Cross-Topic Synoptic Links

Section 3.8 is intensely synoptic. It links to biological molecules (DNA structure, the central dogma, protein synthesis) — the chromatography techniques covered in RP6 of that course are the conceptual ancestor of the modern electrophoretic separations used here. It links to cells and the immune system (cell-cycle regulation, mitosis, the cellular targets of cancer biology). And it links to populations and inheritance (mutation as the raw material for evolution, the population-level distribution of disease-causing alleles). Paper 3 essay prompts on "control of cell processes" or "the importance of DNA" routinely span all four sections.

Required Practical Anchor

Section 3.8 itself has no dedicated required practical, but the molecular techniques described here build directly on RP6 — chromatography, anchored in the biological molecules course. Candidates should be able to discuss separation by size, by charge or by chemical affinity as a general principle that connects chromatographic separation of amino acids, gel-electrophoretic separation of DNA fragments, and the analytical techniques used to verify recombinant protein products.

Revision Strategy

Build a flashcard set distinguishing oncogenes from tumour suppressors with five named examples on each side; rotate weekly until the distinction is automatic. Sketch the PCR cycle and the gel-electrophoresis apparatus from memory in alternating sessions. Write a one-page summary of each clinical example (insulin production, trastuzumab, AAV gene therapy, CRISPR) that you can recall in three minutes. Retrieval practice — closed-book recall — is significantly more effective than rereading; Roediger and Karpicke's work on the testing effect is the canonical reference. Spaced repetition, scheduling reviews at expanding intervals, exploits the forgetting curve documented by Ebbinghaus to lock material into long-term memory. Interleaving transcription factors, cancer biology, recombinant DNA and gene therapy within a single session — rather than blocking one topic at a time — improves discrimination between related mechanisms and is particularly valuable for the synoptic essay on Paper 3.

The single most common preventable mistake on Paper 2 gene-expression items is confusing transcription factors with siRNA or with epigenetic marks. Build a tabular comparison early and revisit it weekly.

Closing

Gene expression and technology is where the foundational molecular biology of 7402 turns into the clinical and biotechnological reality that shapes contemporary medicine and agriculture. The completed Phase 2 course supplies every component AQA examines, from transcription-factor mechanism through cancer biology to the genome era. Start with transcription factors to anchor the regulatory framework, work through epigenetics and stem cells, lock down the oncogene/tumour-suppressor distinction in the cancer-biology lesson, and finish with the biotechnology and gene-therapy applications. The full LearningBro AQA A-Level Biology path walks the whole 7402 sequence end-to-end with worked examples, AI tutor feedback and exam-style practice.